Description

MOREASE SR 200 MG

Indications

MOREASE SR 200 MG is primarily indicated for the management of various psychiatric disorders, including major depressive disorder and generalized anxiety disorder. It may also be prescribed for the treatment of panic disorder, obsessive-compulsive disorder, and certain types of chronic pain. The extended-release formulation allows for once-daily dosing, which can enhance patient compliance and overall treatment outcomes.

Mechanism of Action

MOREASE SR 200 MG contains the active ingredient venlafaxine, which is classified as a serotonin-norepinephrine reuptake inhibitor (SNRI). The drug works by inhibiting the reuptake of serotonin and norepinephrine in the synaptic cleft, thereby increasing the levels of these neurotransmitters in the brain. This dual action is believed to contribute to its antidepressant and anxiolytic effects, making it effective in alleviating symptoms of depression and anxiety.

Pharmacological Properties

Venlafaxine is well-absorbed after oral administration, with peak plasma concentrations typically occurring within 2 to 4 hours. The extended-release formulation of MOREASE SR allows for a gradual release of the medication, maintaining therapeutic levels throughout the day. The drug undergoes extensive metabolism in the liver, primarily by the cytochrome P450 enzyme system, particularly CYP2D6. The elimination half-life of venlafaxine is approximately 5 hours, but this may be extended in the case of its active metabolite, O-desmethylvenlafaxine, which has a half-life of about 11 hours.

Contraindications

MOREASE SR 200 MG is contraindicated in patients with a known hypersensitivity to venlafaxine or any of the excipients in the formulation. It should not be used in conjunction with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing such treatment, as this may lead to serious and potentially life-threatening reactions. Additionally, the drug is contraindicated in patients with uncontrolled narrow-angle glaucoma, as it may increase intraocular pressure.

Side Effects

The use of MOREASE SR 200 MG may be associated with a range of side effects. Commonly reported adverse effects include nausea, dry mouth, dizziness, insomnia, and constipation. Some patients may experience increased sweating or sexual dysfunction. In rare cases, more severe side effects such as hypertension, serotonin syndrome, and suicidal thoughts may occur. It is important for patients to discuss any side effects with their healthcare provider, particularly if they are severe or persistent.

Dosage and Administration

The recommended starting dose of MOREASE SR 200 MG for adults is typically 75 mg per day, which may be increased based on clinical response and tolerability. The maximum recommended dose is 375 mg per day. The medication should be taken with food to enhance absorption and reduce gastrointestinal side effects. It is important for patients to adhere to their prescribed regimen and not to discontinue the medication abruptly, as this may lead to withdrawal symptoms.

Interactions

MOREASE SR 200 MG may interact with a variety of medications, which can affect its efficacy and safety profile. Concomitant use with other central nervous system depressants, such as alcohol or benzodiazepines, may enhance sedative effects. Additionally, the use of venlafaxine with other serotonergic drugs, including certain antidepressants, may increase the risk of serotonin syndrome, a potentially life-threatening condition. Patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking to avoid possible interactions.

Precautions

Before starting MOREASE SR 200 MG, patients should be evaluated for any history of cardiovascular disease, hypertension, or seizures, as the medication may exacerbate these conditions. Caution should also be exercised in patients with a history of bipolar disorder, as the use of antidepressants may trigger manic episodes. Regular monitoring of blood pressure is advised, particularly in patients with a history of hypertension. Pregnant or breastfeeding women should discuss the risks and benefits of treatment with their healthcare provider, as the safety of venlafaxine during pregnancy and lactation has not been fully established.

Clinical Studies

Clinical studies have demonstrated the efficacy of MOREASE SR 200 MG in treating major depressive disorder and generalized anxiety disorder. In randomized controlled trials, patients receiving venlafaxine showed significant improvements in depressive and anxiety symptoms compared to those receiving placebo. The extended-release formulation has been shown to provide a more consistent therapeutic effect with fewer fluctuations in plasma levels, which may contribute to improved patient adherence and satisfaction with treatment.

Conclusion

MOREASE SR 200 MG is an effective option for the treatment of various psychiatric disorders, particularly major depressive disorder and generalized anxiety disorder. Its unique mechanism of action as a serotonin-norepinephrine reuptake inhibitor offers a dual approach to managing symptoms. While generally well-tolerated, it is essential for patients to be aware of potential side effects and drug interactions. Regular follow-up with healthcare providers is crucial to ensure optimal treatment outcomes and to address any concerns that may arise during therapy.